Steven Attia, DO
Hematology & Oncology · Jacksonville, FLNPI 1417912585
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $1,350 of the $1,531 with a category attached, or 88.2%. Trillium Therapeutics USA, LLC accounts for 88.2% of it on its own, with 3 other manufacturers making up the rest. Reporting peaked in 2023 at $1,350 and has fallen 88.1% since, to $161 in 2025. That places this record below the midpoint for hematology & oncology clinicians in FL, where the typical reported total is $3,884.
Across 4 payments — averaging $382.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Trillium Therapeutics USA, LLC$1K
- Davol Inc.$161
- Foundation Medicine, Inc.$14
- Merck$6
Across 1,744 payments — averaging $7984.42 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Deciphera Pharmaceuticals Inc.$10.1M
- PTC Therapeutics, Inc.$1.1M
- Boehringer Ingelheim$569K
- Karyopharm Therapeutics Inc.$394K
- Incyte Corporation$265K
- Blueprint Medicines Corporation$260K
- plus $1.2M from 14 others
What the payments were for
- Consulting fees$1,35088%
- Food & beverage$18112%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Trillium Therapeutics USA, LLC | 1 | $1,350 |
| Davol Inc. | 1 | $161 |
| Foundation Medicine, Inc. | 1 | $14 |
| Merck | 1 | $6 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Bard 3DMax Mesh$161
How this compares
$1,531 in reported general payments places this provider in the 35th percentile of 694 hematology & oncology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Imatinib Mesylate | 20 | $1,372 |
| Prochlorperazine Maleate | 16 | $196 |
| Ondansetron Hcl | 16 | $150 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Jacksonville
- Edith PerezJacksonville$1.1M
- Vamsidhar VelchetiJacksonville$966K
- Arnab BasuJacksonville$440K
- Sikander AilawadhiJacksonville$179K
- James ForanJacksonville$164K
- Asher Chanan KhanJacksonville$109K
- Martin DietrichRockledge$6.2M
- Mark SocinskiOrlando$2.4M
- Tarek MekhailOrlando$2.2M
- Edgardo SantosFort Lauderdale$2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.